APA (7th ed.) Citation

Riedel, R. F., Ballman, K. V., Lu, Y., Attia, S., Loggers, E. T., Ganjoo, K. N., . . . Maki, R. G. (2020). A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study. The oncologist (Dayton, Ohio), 25(11), e1655-e1662. https://doi.org/10.1634/theoncologist.2020-0679

Chicago Style (17th ed.) Citation

Riedel, Richard F., et al. "A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study." The Oncologist (Dayton, Ohio) 25, no. 11 (2020): e1655-e1662. https://doi.org/10.1634/theoncologist.2020-0679.

MLA (9th ed.) Citation

Riedel, Richard F., et al. "A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study." The Oncologist (Dayton, Ohio), vol. 25, no. 11, 2020, pp. e1655-e1662, https://doi.org/10.1634/theoncologist.2020-0679.